Bilthoven Biologicals

Bilthoven Biologicals (BBio) is a vaccine manufacturer headquartered in the Netherlands. The company focuses on the research, development, and production of vaccines targeting infectious diseases. Its products are intended for use in national immunisation programmes as well as for distribution to international public‑health markets. Bilthoven Biologicals operates production facilities that support the supply of routine vaccines. The organisation serves governmental health agencies, procurement organisations, and global vaccine alliances.

While specific employee counts or annual revenue figures are not disclosed in the available sources, the company maintains a dedicated manufacturing site in Bilthoven. Its operational footprint includes laboratories and production lines that comply with European medicinal‑product regulations. Bilthoven Biologicals contributes to the Netherlands’ vaccine sovereignty by providing domestically produced doses for national stockpiles. The firm collaborates with national health authorities and international partners to meet vaccine demand during routine and outbreak scenarios. These activities position it as a component of the broader European vaccine supply chain.

Bilthoven Biologicals distinguishes itself through its specialised expertise in vaccine science and its possession of valuable intellectual property, including research data and proprietary formulations. This concentration of sensitive information made the company a target for cyber‑criminals, as demonstrated by the ransomware incident on 21 September 2022. The Blackcat (ALPHV) group exploited unpatched firewalls and VPN vulnerabilities, encrypted internal servers, and exfiltrated vaccine research, employee data, emails, and documents. Although most production continued, the attack prompted notifications to data‑protection authorities and affected individuals, and led to engagement of cyber‑security experts and preparation of a police report. The incident underscores the organisation’s role as a holder of high‑value biomedical assets within the pharmaceutical sector.